Edition:
India

Biodelivery Sciences Acquires U.S. Commercial Rights To Symproic


Thursday, 11 Apr 2019 

April 10 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES INTERNATIONAL INC - TOTAL 2019 COMPANY NET SALES EXPECTED TO BE $92-$100 MILLION WITH SYMPROIC NET SALES OF $7-$9 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - WILL PAY SHIONOGI, INC., AN INITIAL PAYMENT OF $20 MILLION AND AN ADDITIONAL $10 MILLION IN SIX MONTHS.BIODELIVERY SCIENCES INTERNATIONAL INC - SHIONOGI IS ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS BASED ON NET SALES OF SYMPROIC.BIODELIVERY SCIENCES INTERNATIONAL INC - COMPANY HAS REAFFIRMED ITS EXPECTATION TO BECOME OPERATING CASH FLOW POSITIVE BY END OF 2019..BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECTS LONG-TERM NET SALES POTENTIAL OF ITS PRODUCT PORTFOLIO TO BE IN RANGE OF $325 - $400 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECT TO SEE AN ACCRETIVE CONTRIBUTION TO CASH FLOW IN FIRST HALF OF 2020 FROM SYMPROIC.